Inclusion Criteria:

- Age: >= 13 years and < 100 years

- Relapse of high grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma
multiforme WHO grade IV), histologically proven at first stage of disease
(radiological evidence for recurrence suffices)

- Relapse of glioma, which was grade II at initial diagnosis, but which is grade III
or IV at relapse based on radiological or pathological criteria

- Total or subtotal resection of tumor mass, confirmed by assessment by the
neurosurgeon and by postoperative MRI scan within 72 hours after surgery. The
post-operative assessment should demonstrate residual tumor less than or equal to 2
cm3 as judged by surgeon and on MRI the tumor should only show linear contrast
enhancement at the border of the resection cavity or nodule less than 2 cm3.

- No radiotherapy and/or chemotherapy received for at least 1 month before first DC
vaccination is to be administered

- No treatment with corticosteroids or salicylates for at least 1 week before first
vaccination. Corticosteriod therapy should be rapidly weaned within 1-2 weeks after
surgery

- Life expectancy > 3 months

- Written consent by patient or parent(s) (if patient is < 18 years) on an
institutional review board (IRB)-approved informed consent form prior to any
study-specific evaluation. Assent is required from children as per UM IRB
guidelines.

- Adequate organ function (to be measured at enrollment)

- Absolute neutrophil count (ANC) >750/L

- Lymphocytes > 500/L

- Platelets > 75,000/L

- Hemoglobin > 9 g/dL

- AST/ALT < 2.5 X ULN; if liver metastases, < 5 X ULN

- Serum Creatinine < 1.5 X ULN

- Total Bilirubin < 3 X ULN

- Albumin > 2 g/dL

- ECOG performance status of 0 or 1

- Subjects must agree to use adequate method of contraception or abstinence throughout
and up to 4 weeks after the study treatment completion.

- Capable of understanding the investigational nature, potential risks and benefits of
the study and able to provide valid informed consent.

- Karnofsky score above 70 or ECOG status of 0 or 1.

Exclusion Criteria:

- Pregnancy

- Breast feeding females

- Any concomitant participation in other therapeutic trials

- Virus serology positive for HIV(testing is not required in the absence of clinical
suspicion)

- Documented immunodeficiency

- Documented autoimmune disease

- Mandatory treatment with corticosteroids or salicylates prior to first
vaccination

- 3.3.8 Other active malignancies

- Patients with unresectable tumors, for instance pontine gliomas, are excluded.

- Refusal to use adequate contraception for fertile patients (females and males) during
the study and for 30 days after the last dose of study treatment.

- Any serious or uncontrolled medical or psychiatric condition that in the opinion of
the investigator makes the patient not able to participate in the study.